Nobuhisa Ishikawa

Hiroshima, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Takayasu Arteritis in a Middle-aged Woman Following Prolonged Subsequent Fever after COVID-19 Infection: An Early Diagnosis Using Contrast-enhanced CT.

Takayasu Arteritis in a Middle-aged Woman Following Prolonged Subsequent Fever after COVID-19 Infection: An Early Diagnosis Using Contrast-enhanced CT.

Journal: Internal medicine (Tokyo, Japan)

Published: January 14, 2026

Bridging therapy with airway stent placement followed by immune checkpoint inhibitors in patients with lung cancer and malignant airway disorders: A retrospective study.

Bridging therapy with airway stent placement followed by immune checkpoint inhibitors in patients with lung cancer and malignant airway disorders: A retrospective study.

Journal: Respiratory investigation

Published: November 28, 2025

Effectiveness and safety of combination immunotherapy with or without ipilimumab according to PD-L1 expression in patients with non-small cell lung cancer: a multi-center retrospective cohort study.

Effectiveness and safety of combination immunotherapy with or without ipilimumab according to PD-L1 expression in patients with non-small cell lung cancer: a multi-center retrospective cohort study.

Journal: Translational lung cancer research

Published: November 10, 2025

Real-world clinical utility and challenges of comprehensive genomic profiling for advanced solid tumors in a community health institution.

Real-world clinical utility and challenges of comprehensive genomic profiling for advanced solid tumors in a community health institution.

Journal: International journal of clinical oncology

Published: June 18, 2025

Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.

Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.

Journal: JTO clinical and research reports

Published: June 16, 2025

Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial.

Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial.

Journal: American journal of respiratory and critical care medicine

Published: June 13, 2025

Predictive value of Eastern Cooperative Oncology Group performance status and body mass index for antifibrotic tolerability and prognosis in patients with idiopathic pulmonary fibrosis.

Predictive value of Eastern Cooperative Oncology Group performance status and body mass index for antifibrotic tolerability and prognosis in patients with idiopathic pulmonary fibrosis.

Journal: Respiratory medicine

Published: May 14, 2025

Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial.

Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial.

Journal: The Lancet. Respiratory medicine

Published: April 08, 2025

Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study.

Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study.

Journal: Respiratory investigation

Published: April 02, 2025

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).

Journal: Therapeutic advances in medical oncology

Published: February 07, 2025

Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR-TKI Administration Using Droplet Digital PCR in Non-small-cell Lung Cancer With EGFR Mutation.

Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR-TKI Administration Using Droplet Digital PCR in Non-small-cell Lung Cancer With EGFR Mutation.

Journal: Cancer diagnosis & prognosis

Published: February 02, 2025

Prognostic prediction for newly diagnosed patients with idiopathic interstitial pneumonia: JIPS Registry (NEJ030).

Prognostic prediction for newly diagnosed patients with idiopathic interstitial pneumonia: JIPS Registry (NEJ030).

Journal: Respiratory investigation

Published: December 18, 2024

Showing 1-12 of 77

Last Updated: 09/26/2026